Zymeworks (ZYME) | Stock Overview & Key Data
Zymeworks Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $59.03 on January 11, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Zymeworks
ZYME
|
1.96B Small-cap | -2.80% | -2.80% | -1.52% | -10.44% | -12.62% | 80.58% | 181.77% | -36.88% | 76.00% | 76.00% | 76.00% |
|
Vertex
VRTX
|
109.45B Large-cap | 1.69% | 3.09% | -3.36% | -1.15% | -0.37% | -2.31% | 27.89% | 136.85% | 413.01% | 888.51% | 1,245.83% |
|
Regeneron
REGN
|
80.98B Large-cap | 0.60% | -11.93% | -18.75% | -18.29% | -20.78% | 15.66% | -21.83% | 13.80% | 72.82% | 1,033.17% | 4,804.97% |
|
Adaptive
ADPT
|
2.13B Mid-cap | 8.83% | 18.51% | 58.40% | 28.26% | 44.06% | 70.54% | 109.77% | -55.39% | -63.56% | -63.56% | -63.56% |
|
Agios
AGIO
|
1.48B Small-cap | -3.93% | 9.18% | 12.72% | 48.46% | 45.73% | -14.11% | 14.27% | -51.27% | -37.95% | 3.26% | 3.26% |
|
Ocular Therapeutix
OCUL
|
2.07B Mid-cap | 10.17% | -1.86% | 4.17% | -36.56% | -23.94% | 2.41% | 85.86% | -33.83% | 65.56% | -32.02% | -32.02% |
Ownership & Short Interest
Calculate Your Zymeworks Investment Returns
Long-Term Investment Performance Analysis
Zymeworks stock price in Apr 2017 was $13.00, A $1,000.00 lump sum investment in Zymeworks made 9 years ago would be worth approximately $1,789.23 today, representing a solid return of 78.92%. This translates to an annualized return (CAGR) of 6.57%.
9 Years 1 Month Investment Scenario (Apr 2017 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is ZYME's 52-week high and low?
- In the last 52 weeks, Zymeworks reached a high of $29.75 (on April 27, 2026) and a low of $11.51 (on August 8, 2025).
- What is the market cap and P/E ratio for ZYME?
- Curious about Zymeworks's size and valuation? Its market capitalization stands at 1.96B. When it comes to valuation, the P/E ratio (trailing twelve months) is 3.79, and the forward P/E (looking ahead) is 33.43.
- Does ZYME pay dividends? If so, what's the yield?
- As for dividends, Zymeworks isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Zymeworks's main competitors or similar companies to consider before investing?
When looking at Zymeworks, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology -2.31% 27.89% Regeneron
REGN80.98B Healthcare Biotechnology 15.66% -21.83% Adaptive
ADPT2.13B Healthcare Biotechnology 70.54% 109.77% Agios
AGIO1.48B Healthcare Biotechnology -14.11% 14.27% Ocular Therapeutix
OCUL2.07B Healthcare Biotechnology 2.41% 85.86% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Zymeworks Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Zymeworks's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -26.72%, the Debt to Equity ratio from the most recent quarter is 6.80, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for ZYME?
- Looking at Zymeworks's growth, its revenue over the trailing twelve months (TTM) was $106M. Compared to the same quarter last year (YoY), quarterly revenue grew by -91.90%, and quarterly earnings saw a YoY growth of -91.90%.
- How much of ZYME stock is held by insiders and institutions?
- Wondering who owns Zymeworks stock? Company insiders (like executives and directors) hold about 1.26% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 98.45%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.